Cancer, Signal Transduction and Nanotechnology

被引：1

作者：

Sengupta, Poulomi ^{[3
]}

Basu, Sudipta ^{[2
,3
]}

Sengupta, Shiladitya ^{[1
,2
,3
]}

机构：

[1] MIT, Harvard Mit Div Hlth Sci & Technol, BWH HST Ctr Biomed Engn, Dept Med, Cambridge, MA 02139 USA

[2] Harvard Univ, Sch Med, BWH HST Ctr Biomed Engn, Dept Med, Cambridge, MA 02139 USA

[3] Brigham & Womens Hosp, BWH HST Ctr Biomed Engn, Dept Med, Cambridge, MA 02139 USA

来源：

CURRENT DRUG DELIVERY | 2011年 / 8卷 / 03期

关键词：

Nanotechnology; drug delivery; signaling pathways; nanoparticles; cancer; EPIDERMAL-GROWTH-FACTOR; RECEPTOR TYROSINE KINASES; BIOLOGICAL EVALUATION; POTENT INHIBITOR; PI3; KINASE; CONSTITUTIVE ACTIVATION; MONOCLONAL-ANTIBODY; 3-KINASE INHIBITOR; ANTITUMOR-ACTIVITY; SUPPRESSES GROWTH;

D O I：

10.2174/156720111795256147

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Understanding the mechanisms underlying different cellular signaling pathways implicated in the pathogenesis of cancer are leading to the identification of novel drug targets as well as novel drug candidates. Multiple targeted therapeutics that modulate aberrant molecular pathways have already reached the clinic. However, targeted therapeutics can exert mechanism-driven side effects as a result of the implication of the molecular target in normal physiological functions besides tumorigenesis. We hypothesize that targeted therapeutics can be optimized by merging them with nanotechnology, which offers the potential for preferential targeting to the tumor, resulting in increased intratumoral concentrations of the active agent with reduced distribution to other parts of the body. This review will address some of the emerging concepts that integrate these two disciplines to engineer novel nanovectors that target different signaling pathways.

引用

页码：254 / 260

页数：7

共 93 条

[51] Immunonanoshells for targeted photothermal ablation of tumor cells [J].

Lowery, Amanda R. ;

Gobin, Andre M. ;

Day, Emily S. ;

Halas, Naomi J. ;

West, Jennifer L. .

INTERNATIONAL JOURNAL OF NANOMEDICINE, 2006, 1 (02) :149-154

[52] Targeting the PI3K-Akt pathway in human cancer: Rationale and promise [J].

Luo, J ;

Manning, BD ;

Cantley, LC .

CANCER CELL, 2003, 4 (04) :257-262

[53] SPECIFICITY OF RECEPTOR TYROSINE KINASE SIGNALING - TRANSIENT VERSUS SUSTAINED EXTRACELLULAR SIGNAL-REGULATED KINASE ACTIVATION [J].

MARSHALL, CJ .

CELL, 1995, 80 (02) :179-185

[54]

Metro G, 2008, EXPERT OPIN PHARMACO, V9, P2583, DOI [10.1517/14656566.9.15.2583, 10.1517/14656566.9.15.2583 ]

[55] Nanoparticle imaging of integrins on tumor cells [J].

Montet, Xavier ;

Montet-Abou, Karin ;

Reynolds, Fred ;

Weissleder, Ralph ;

Josephson, Lee .

NEOPLASIA, 2006, 8 (03) :214-222

[56] Internally Cationic Polyamidoamine PAMAM-OH Dendrimers for siRNA Delivery: Effect of the Degree of Quaternization and Cancer Targeting [J].

Patil, Mahesh L. ;

Zhang, Min ;

Taratula, Oleh ;

Garbuzenko, Olga B. ;

He, Huixin ;

Minko, Tamara .

BIOMACROMOLECULES, 2009, 10 (02) :258-266

[57] Nanocarriers as an emerging platform for cancer therapy [J].

Peer, Dan ;

Karp, Jeffrey M. ;

Hong, SeungPyo ;

FaroKHzad, Omid C. ;

Margalit, Rimona ;

Langer, Robert .

NATURE NANOTECHNOLOGY, 2007, 2 (12) :751-760

[58] Intravenous tolerance of a nanoparticle-based formulation of doxorubicin in healthy rats [J].

Pereverzeva, E. ;

Treschalin, I. ;

Bodyagin, D. ;

Maksimenko, O. ;

Kreuter, J. ;

Gelperina, S. .

TOXICOLOGY LETTERS, 2008, 178 (01) :9-19

[59]

Presta LG, 1997, CANCER RES, V57, P4593

[60] Tumorigenesis -: RAF/RAS oncogenes and mismatch-repair status [J].

Rajagopalan, H ;

Bardelli, A ;

Lengauer, C ;

Kinzler, KW ;

Vogelstein, B ;

Velculescu, VE .

NATURE, 2002, 418 (6901) :934-934

← 1 2 3 4 5 6 7 8 9 10 →